within Pharmacolibrary.Drugs.ATC.A;

model A10BK04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.00018666666666666666,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0855,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011683333333333332,
    Tlag           = 60,            
    Vdp             = 0.06659999999999999,
    k12             = 15.1,
    k21             = 15.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BK04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ertugliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus to improve glycemic control. It is approved for clinical use and generally administered orally as a tablet.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult subjects (both sexes), after single and multiple oral doses under fasted and fed conditions.</p><h4>References</h4><ol><li><p>Sahasrabudhe, V, Terra, SG, Hickman, A, Saur, D, Raje, S, Shi, H, Matschke, K, Zhou, S, &amp; Cutler, DL (2018). Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. <i>Clinical therapeutics</i> 40(10) 1701–1710. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2018.06.015&quot;>10.1016/j.clinthera.2018.06.015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30224193/&quot;>https://pubmed.ncbi.nlm.nih.gov/30224193</a></p></li><li><p>Fediuk, DJ, Nucci, G, Dawra, VK, Cutler, DL, Amin, NB, Terra, SG, Boyd, RA, Krishna, R, &amp; Sahasrabudhe, V (2020). Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. <i>Clinical pharmacokinetics</i> 59(8) 949–965. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00875-1&quot;>10.1007/s40262-020-00875-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32337660/&quot;>https://pubmed.ncbi.nlm.nih.gov/32337660</a></p></li><li><p>Powell, J, &amp; Garland, SG (2019). Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus. <i>The Annals of pharmacotherapy</i> 53(5) 478–485. DOI:<a href=&quot;https://doi.org/10.1177/1060028018818829&quot;>10.1177/1060028018818829</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30522346/&quot;>https://pubmed.ncbi.nlm.nih.gov/30522346</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BK04;
